Growth Hormone
Peptides
Compound profile

Tesamorelin: Approved GHRH Analogue

Tesamorelin is an FDA-approved synthetic GHRH analogue indicated for reduction of excess abdominal fat in HIV-associated lipodystrophy.

On this page

What it is

Tesamorelin is a synthetic 44-amino-acid GHRH analogue modified for stability. FDA-approved (2010) for reduction of visceral adipose tissue in HIV-associated lipodystrophy.

Evidence snapshot

Category: Growth Hormone. Status: Human Trials. See the references section below for the underlying primary sources.

Mechanism

Binds the GHRH receptor, stimulating endogenous GH release and downstream IGF-1 elevation. Pulsatile GH release more closely mimics physiological patterns than exogenous GH.

Key research findings

Phase 3 trials demonstrated significant reduction in visceral adipose tissue with tesamorelin treatment in HIV-associated lipodystrophy.

Limits of the evidence

Limited indication (HIV-associated lipodystrophy). IGF-1 elevations can exceed physiological range; monitoring recommended. Off-label use in other indications lacks rigorous trial support.

Continue reading

Tissue Repair

BPC-157

Synthetic pentadecapeptide derived from a gastric juice protein, studied across hundreds of preclinical reports for tissue regeneration and cytoprotection.
Read Guid
Tissue Repair

TB-500 (Thymosin Beta-4 fragment)

Synthetic fragment of Thymosin Beta-4, a 43-amino-acid peptide investigated for its role in actin regulation, cell migration, and wound healing.
Read Guid
Peptide Protocols

BPC-157 + TB-500

Combined tissue-repair peptides with complementary mechanisms — the synergy hypothesis examined critically against the available preclinical record.
Read Guid
Growth Hormone · Research

Ipamorelin

Selective pentapeptide agonist of the growth hormone secretagogue receptor (GHSR-1a) studied for targeted GH release with minimal effect on cortisol, ACTH and prolactin.
Read Guid